

Pancreatic involvement of Lymphoma as determined by F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography

© Zehra Pinar Koç^{1*} © Pinar Pelin Özcan² © Serkan Yaraş³

*Corresponding Author

^{1,2}Mersin University, Faculty of Medicine, Department of Nuclear Medicine, Mersin, Turkey

³Mersin University, Faculty of Medicine, Department of Gastroenterology, Mersin, Turkey

Abstract

The most important imaging modality in the Lymphoma is F-18 FDG PET/CT. Although pancreatic involvement of Lymphoma is rare this is the report of three cases with diagnosis of Lymphoma who has pancreatic involvement as well as disseminated disease presentation as demonstrated by F-18 FDG PET/CT.

Keywords: *pancreas involvement, lymphoma, fluorodeoxyglucose, positron emission tomography/computed tomography.*

Introduction

Although pancreatic involvement of the Lymphoma is rare in case of hypermetabolic lesions on the pancreas in a patient with diagnosis of Lymphoma it should be considered. Diffuse FDG uptake in the enlarged pancreas might be associated with autoimmune pancreatitis which is characterized by inflammation of the pancreas (1). There is several case reports about the disease progress in the literature including cases with pancreatic and extrapancreatic disease presented with FDG PET/CT results (1-5). However pancreatic involvement of Lymphoma might be presented in several imaging characteristics in FDG PET/CT as analyzed in a case series previously in the literature (6). The aim of this analysis of this specific case series was to evaluate the FDG PET/CT as well as clinical findings in this group of patients.

Address for Correspondence: Zehra Pinar Koç, Mersin University Training and Research Hospital, Clinic of Nuclear Medicine, Mersin, Turkey

Phone: + 90-324-2410000/22524 **E-mail:** zehrapinarkoc@gmail.com **ORCID ID:** <https://orcid.org/0000-0002-3274-5790> **Received:**

04.04.2024 Accepted: 14.05.2024 Published: 14.05.2024

Case 1: A male patient at the age of 73 years who was firstly diagnosed with multiple cervical and abdominal lymph nodes was referred for FDG PET/CT examination. The imagings showed disseminated disease with lymph node, bone marrow and spleen involvement as well as diffuse hypermetabolic swelling of pancreas (Figure 1). The patient died within a week after imaging examination.




Figure 1: Lymph nodes, bone marrow and spleen, and widespread involvement of the pancreas are observed.

Case 2: 62 years old male patient with the diagnosis of Mycosis Fungoides attended for FDG PET/CT imaging for restaging after chemotherapy. The imaging revealed disseminated disease with lymph node and bone marrow involvement and additional cutaneous lesions with diffuse pancreas enlargement and FDG uptake (Figure 2). The IgG level of the patient was normal. The patient died one month after the imaging.



Figure 2: Diffuse pancreatic enlargement is seen on FDG PET/CT cross-sectional imaging.

Discussion

The pancreatic involvement (primary or secondary) of Lymphoma is a significantly rare finding (1). The FDG uptake patterns of these lesions were classified in a study including 9 patients who has this rare finding focal, segmental and diffuse uptake patterns (6). According to that analysis the pancreatic head was the most common involvement site (6). Previous studies confirm the role of F-18 FDG PET/CT in nodal and extranodal involvement with higher diagnostic sensitivity and specificity compared to Contrast Enhanced CT (7). Autoimmune pancreatitis FDG uptake is relatively lower compared to pancreatic Lymphoma (8). There are several case reports about pancreatic involvement as a multiple organ disease in patients with Burkitt Lymphoma in HIV positive patients (9). Usually, the pancreas involvement has been presented as a part of multiple organ involvement (10). In another case report it was determined in a patient with primary skeletal muscle Lymphoma (11). All these findings also suggest as it is reported in this case presentation, FDG PET-CT is a cornerstone of Lymphoma imaging and additionally it might determine unexpected involvement sites with high diagnostic accuracy.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Concept: Z.P.K., P.P.O., S.Y., **Design:** Z.P.K., **Supervision:** Z.P.K., P.P.O., S.Y., **Data Collection and/or Processing:** Z.P.K., P.P.O., S.Y., **Analysis and/or Interpretation:** Z.P.K., P.P.O., S.Y., **Literature Review:** Z.P.K., **Writer:** Z.P.K.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

References

1. Nakajo M, Jinnouchi S, Noguchi M, Uozumi K, Tanabe H, Tateno R, Nakajo M. FDG PET and PET/CT monitoring of autoimmune pancreatitis associated with extrapancreatic autoimmune disease. *Clin Nucl Med*. 2007 Apr;32(4):282-5. doi: 10.1097/01.rlu.0000257295.12017.ab.
2. Nakajo M, Jinnouchi S, Fukukura Y, Tanabe H, Tateno R, Nakajo M. The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions. *Eur J Nucl Med Mol Imaging*. 2007 Dec;34(12):2088-95. doi: 10.1007/s00259-007-0562-7.
3. Nanni C, Romagnoli R, Rambaldi I, Caroli P, Matteucci F, Ambrosini V, Re G, Fanti S. FDG PET/CT in autoimmune pancreatitis. *Eur J Nucl Med Mol Imaging*. 2014 Jun;41(6):1264-5. doi: 10.1007/s00259-014-2699-5.
4. Santhosh S, Bhattacharya A, Harisankar CN, Kochhar R, Mittal BR. Role of 18F-FDG PET/CT in the management of a case of autoimmune pancreatitis with extrapancreatic manifestations. *Clin Nucl Med*. 2013 Nov;38(11):e423-5. doi: 10.1097/RLU.0b013e31827086b5.
5. Nakajo M, Jinnouchi S, Fukukura Y, Tanabe H, Tateno R, Nakajo M. The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions. *Eur J Nucl Med Mol Imaging*. 2007 Dec;34(12):2088-95. doi: 10.1007/s00259-007-0562-7.
6. Dong A, Cui Y, Gao L, Wang Y, Zuo C, Yang J. Patterns of FDG uptake in pancreatic non-Hodgkin's lymphoma lesions. *Abdom Imaging*. 2014 Feb;39(1):175-86. doi: 10.1007/s00261-013-0041-5.

7. Schaefer, N. G., Hany, T. F., Taverna, C., Seifert, B., Stumpe, K. D., von Schulthess, G. K., & Goerres, G. W. (2004). Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?. *Radiology*, 232(3), 823–829. <https://doi.org/10.1148/radiol.2323030985>
8. Zhang, J., Shao, C., Wang, J., Cheng, C., Zuo, C., Sun, G., Cui, B., Dong, A., Liu, Q., & Kong, L. (2013). Autoimmune pancreatitis: whole-body 18F-FDG PET/CT findings. *Abdominal imaging*, 38(3), 543–549. <https://doi.org/10.1007/s00261-012-9966-3>
9. Sireesha P, Nithya V, Surya G, Hemalatha DS, Kalawat T, Kumar VS, Priya RR. A Rare Finding of Pancreatic Involvement in a Case of Burkitt's Lymphoma. *Indian J Nucl Med*. 2023 Jan-Mar;38(1):59-62. doi: 10.4103/ijnm.ijnm_108_22.
10. Arslan E, Aksoy T, Alçın G, Ermantaş N, Özlük Y, Yeğen G, Çermik TF. Diffuse Large B-Cell Non-Hodgkin Lymphoma Involving Multiple Different Organs in a Young Adult with 18F-FDG PET/CT. *Mol Imaging Radionucl Ther*. 2022 Feb 2;31(1):72-74. doi: 10.4274/mirt.galenos.2021.28190.
11. Farahmandfar F, Shakeri S, Moradian S, Shahlai S, Sadeghi R. Primary skeletal muscle lymphoma with unusual soft tissue metastases in the stomach and pancreas detected by 18F-FDG PET/CT. *Nucl Med Rev Cent East Eur*. 2020;23(2):108-109. doi: 10.5603/NMR.2020.0021.

© Author(s) 2022. This work is distributed under <https://creativecommons.org/licenses/by-sa/4.0/>

